CEO and Chairman of SLAM BioTherapeutics, an oncology biotech developing a platform of first-in-class antibodies, ADCs and bispecifics to impact the lives of patients with life-threatening cancers. Venture investor collaborating with distinguished co-investors in life science early-stage businesses. Board member and investor in UltraSight, NanoDrops, Lentechs and TearClear. Served as executive and officer at Bausch + Lomb during the transformation and sale for $8.7 Billion. CEO and board member of RxSight/Calhoun Vision which is now public. Co-authored The Merger Dividend, published in the Harvard Business Review. Featured in the Wall Street Journal, Bloomberg Businessweek, Chief Executive Magazine and Pharmaceutical Executive. Bachelor’s degree from Boston University, and a Master of Management from McGill University.